All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Fox Chase Cancer Center’s Daniel J. Campbell Receives Crystal Eagle Leadership Award From American Society for Healthcare Engineering

October 10th 2024

Daniel J. Campbell, TBE, CHFM, FASHE, received the Crystal Eagle Leadership Award from the American Society for Healthcare Engineering.

Talazoparib Plus Enzalutamide Improves OS in mCRPC

October 10th 2024

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

October 10th 2024

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Molecularly Targeted Therapeutics Are Precisely Aimed

October 10th 2024

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm

October 10th 2024

Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

October 10th 2024

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases

October 9th 2024

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 9th 2024

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI Cancers

October 9th 2024

OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

October 9th 2024

The FDA has granted orphan drug designation to namodenoson for the treatment of patients with pancreatic cancer.

LBL-024 Receives Breakthrough Therapy Designation in China for Extrapulmonary Neuroendocrine Carcinoma

October 9th 2024

LBL-024 received breakthrough therapy designation in China for pretreated advanced extrapulmonary neuroendocrine carcinoma.

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

October 9th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

October 9th 2024

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

October 9th 2024

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

October 8th 2024

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

October 8th 2024

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

October 8th 2024

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.